Adult Dosing
Adjunct analgesic anesthesia
General Surgery (with nitrous oxide/oxygen in whom endotracheal intubation and mechanical ventilation required)
- 1-2 mcg/kg IV (expected duration of anesthesia 1 to 2 hours)
- Maintenance: 10-25 mcg IV increments as needed when movement and/a changes in vital signs indicate surgical stress or lightening of analgesia
- Max: 1 mcg/kg/hr of expected surgical time
Notes:- Administer 75% or more of total dosage prior to intubation by either slow injection or infusion titrated to individual patient response
- Use with neuromuscular blocking agent
- Monitor vital signs routinely
- Reduce the dose in elderly and debilitated patients
- Reduce the dose if benzodiazepines, barbiturates, inhalation agents, other opioids or other central nervous system depressants are used concomitantly
- Titrate the dose as per individual patient response
Major surgery (with nitrous oxide/oxygen in whom endotracheal intubation and mechanical ventilation required)
- 2 -8 mcg/kg IV (expected duration of anesthesia 2-8 hours)
- Maintenance: 10 to 50 mcg IV increments as needed when movement and/a changes in vital signs indicate surgical stress or lightening of analgesia
- Max: 1 mcg/kg/hr of expected surgical time
Notes:- Administer 75% or less of the total calculated dosage by slow injection or infusion prior to intubation, titrated to individual patient response
- At above mentioned dosage there is attenuation of sympathetic reflex activity in response to surgical stimuli, provide hemodynamic stability, and provide relatively rapid recovery
- Use with neuromuscular blocking agent
- Monitor vital signs routinely
- Reduce the dose in elderly and debilitated patients
- Reduce the dose if benzodiazepines, barbiturates, inhalation agents, other opioids or other central nervous system depressants are used concomitantly
Anesthesia induction
Complicated/prolonged major surgery
Notes:- Use with neuromuscular blocking agent
- Monitor vital signs routinely
- Reduce the dose in elderly and debilitated patients
- Administer higher doses only if qualified personnel and adequate facilities are available for the management of postoperative respiratory depression
- Dosage in this range of up to 25 mcg/kg attenuate catecholamine release
- Dosage of 25-30 mcg/kg block sympathetic response including catecholamine release
- Higher doses indicated in patients undergoing major surgical procedures requiring endotracheal intubation and mechanical ventilation (e.g. cardiovascular surgery and neurosurgery)
- Observe postoperatively and give mechanical ventilation at higher dose range (risk of extended postoperative respiratory depression)
- Reduce the dose if benzodiazepines, barbiturates, inhalation agents, other opioids or other central nervous system depressants are used concomitantly
- Titrate the dose as per individual patient response
Anesthesia maintenance
- 0.5-10 mcg/kg IV
- Max: 30 mcg/kg/procedure (maintenance infusion rate should be based upon the induction dose)
Notes:- Use with neuromuscular blocking agent
- Monitor vital signs routinely
- Reduce the dose in elderly and debilitated patients
- Reduce the dose if benzodiazepines, barbiturates, inhalation agents, other opioids or other central nervous system depressants are used concomitantly
- Titrate the dose as per individual patient response
Obstetric analgesia
- 10-15 mcg epidural qhr with 10 mL bupivacaine 0.125% with or without epinephrine
- Max: 3 doses
Notes:- Slowly inject while administering epidurally
- Mix sufentanil and bupivacaine together before administration
- Ensure proper placement of the needle or catheter in the epidural space before administration to avoid unintentional intravascular or intrathecal administration
- Unintentional intravascular injection could result in a potentially serious overdose, including acute truncal muscular rigidity and apnea
- Unintentional intrathecal injection of full sufentanil, bupivacaine epidural doses and volume can cause effect of high spinal anesthesia including prolonged paralysis and delayed recovery
- Verify placement and integrity of the catheter prior to administration of any additional epidural medications if inadequate analgesia
- Closely monitor respiration following each administration of epidural injection of sufentanil
- Monitor vital signs routinely
- Reduce the dose in elderly and debilitated patients
Pediatric Dosing
Adjunct analgesic anesthesia
General Surgery (with nitrous oxide/oxygen in whom endotracheal intubation and mechanical ventilation required)
12-18 yrs
- 1-2 mcg/kg IV (expected duration of anesthesia 1 to 2 hours)
- Maintenance: 10-25 mcg IV increments as needed when movement and/a changes in vital signs indicate surgical stress or lightening of analgesia
- Max: 1 mcg/kg/hr of expected surgical time
Notes:- Administer 75% or more of total dosage prior to intubation by either slow injection or infusion titrated to individual patient response
- Use with neuromuscular blocking agent
- Monitor vital signs routinely
- Reduce the dose in elderly and debilitated patients
- Reduce the dose if benzodiazepines, barbiturates, inhalation agents, other opioids or other central nervous system depressants are used concomitantly
- Titrate the dose as per individual patient response
Major surgery (with nitrous oxide/oxygen in whom endotracheal intubation and mechanical ventilation required)
12-18 yrs
- 2-8 mcg/kg IV (expected duration of anesthesia 2 to 8 hours)
- Maintenance: 10-50 mcg IV increments as needed when movement and/a changes in vital signs indicate surgical stress or lightening of analgesia
- Max: 1 mcg/kg/hr of expected surgical time
Notes:- Administer 75% or more of total dosage prior to intubation by either slow injection or infusion titrated to individual patient response
- At above mentioned dosage there is attenuation of sympathetic reflex activity in response to surgical stimuli, provide hemodynamic stability, and provide relatively rapid recovery
- Use with neuromuscular blocking agent
- Monitor vital signs routinely
- Reduce the dose if benzodiazepines, barbiturates, inhalation agents, other opioids or other central nervous system depressants are used concomitantly
Anesthesia induction
Complicated/prolonged major surgery
12-18 yrs
Notes:- Use with neuromuscular blocking agent
- Monitor vital signs routinely
- Reduce the dose in elderly and debilitated patients
- Administer higher doses only if qualified personnel and adequate facilities are available for the management of postoperative respiratory depression
- Dosage in this range of up to 25 mcg/kg attenuate catecholamine release
- Dosage of 25-30 mcg/kg block sympathetic response including catecholamine release
- Higher doses indicated in patients undergoing major surgical procedures requiring endotracheal intubation and mechanical ventilation (e.g. cardiovascular surgery and neurosurgery)
- Observe postoperatively and give mechanical ventilation at higher dose range (risk of extended postoperative respiratory depression)
- Reduce the dose if benzodiazepines, barbiturates, inhalation agents, other opioids or other central nervous system depressants are used concomitantly
- Titrate the dose as per individual patient response
<12 yrs (Undergoing CV surgery)
- 10-25 mcg/kg IV with 100% oxygen
Notes:- Half life is increased in neonates and more with cardiovascular disease
- Use with neuromuscular blocking agent
- Monitor vital signs routinely
- Reduce the dose if benzodiazepines, barbiturates, inhalation agents, other opioids or other central nervous system depressants are used concomitantly
- Titrate the dose as per individual patient response
Anesthesia maintenance
12-18 yrs
- 0.5-10 mcg/kg IV
- Max: 30 mcg/kg/procedure (maintenance infusion rate should be based upon the induction dose)
Notes:- Use with neuromuscular blocking agent
- Monitor vital signs routinely
- Reduce the dose in elderly and debilitated patients
- Reduce the dose if benzodiazepines, barbiturates, inhalation agents, other opioids or other central nervous system depressants are used concomitantly
- Titrate the dose as per individual patient response
< 12 yrs (Undergoing CV surgery)
- 25-50 mcg IV
- Half life is increased in neonates and more with cardiovascular disease
- Use with neuromuscular blocking agent
- Monitor vital signs routinely
- Reduce the dose if benzodiazepines, barbiturates, inhalation agents, other opioids or other central nervous system depressants are used concomitantly
- Titrate the dose as per individual patient response
[Outline]
- Only persons specifically trained in the use of IV & epidural anesthetics and management of the respiratory effects of potent opioids should administer this drug
- Keep availability of an opioid antagonist, resuscitative and intubation equipment and oxygen
- Prior to catheter insertion take patients history (such as infection at the injection site, bleeding diathesis, anticoagulant therapy, etc.), evaluate especially to assess benefit vs risk potential
- Unintentional intravascular injection or intravenous administration during epidural administration may cause skeletal muscle rigidity (particularly of the truncal muscles) whose incidence and severity is dose related. The muscular rigidity with sufentanil may appear with a more rapid onset of action than that seen with fentanyl. There may be muscular rigidity which involves the skeletal muscles of the neck and extremities. To reduce the incidence of muscular rigidity associated with IV use administer upto 1/4 of the full paralyzing dose of a non-depolarizing neuromuscular blocking agent just prior to administration of sufentanil (at dosages of up to 8 mcg/kg). Administer full paralyzing dose of a neuromuscular blocking agent following loss of consciousness if sufentanil is used at dose of >8 mcg/kg titrated by slow intravenous infusion. Simultaneously administer sufentanil and a full paralyzing dose of a neuromuscular blocking agent when sufentanil is used in rapid administered anesthetic dosages (>8 mckg). Select the neuromuscular blocking agents which is compatible with the patient's cardiovascular status
- Monitor postoperatively and patients ventilation after sufentanil administration in facilities which are fully equipped to manage all degrees of respiratory depression
- Reduce initial dose of sufentanil in elderly and debilitated patients and considered its effect in determining supplemental doses. Monitor vital signs continously
- High doses of sufentanil with nitrous oxide may produce cardiovascular depression
- Use opioid antagonists such as naloxone in case of respiratory depression, maintain appropiate surveillance. There is increase risk of respiratory depression when sufentanil is administered in combination with volatile inhalational agents and/or other central nervous system depressants such as barbiturates, tranquilizers, and other opioids. Monitor postoperatively to ensure adequate spontaneous breathing and its maintainance prior to discharge. Closely monitor respiration following each administration of an epidural injection of sufentanil
- Ensure proper placement of the needle or catheter in the epidural space before administration to avoid unintentional intravascular or intrathecal administration. Unintentional intravascular injection could result in a potentially serious overdose, including acute truncal muscular rigidity and apnea. Unintentional intrathecal injection of full sufentanil, bupivacaine epidural doses and volume can cause effect of high spinal anesthesia including prolonged paralysis and delayed recovery. Verify placement and integrity of the catheter prior to administration of any additional epidural medications if inadequate analgesia. Slowly inject while administering epidurally
- While selecting a neuromuscular blocking agent consider hemodynamic effects and degree of skeletal muscle relaxation required. Risk of increase in heart rate during sufentanil-oxygen anesthesia due to high doses of pancuronium. Bradycardia and hypotension have been reported with other muscle relaxants during sufentanil-oxygen anesthesia, risk increases with calcium channel and/or beta-blockers
- Reduce the dose of sufentanil with combined treatment with CNS depressants. Concomitant sufentanil and benzodiazepines may result in a decrease in mean arterial pressure and systemic vascular resistance
- Sufentanil may obscure the clinical course of patients with head injuries
- Caution advised in patients with pulmonary disease, decreased respiratory reserve or potentially compromised respiration. Additionally opioids in such patients decrease respiratory drive and increase airway resistance
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Elderly patients
- Debilitated patients
- Neonates
- Concomitant calcium channel and beta blockers
- Concomitant CNS depressants
- Head injuries
- Pulmonary disease
- Decreased respiratory reserve
- Compromised respiration
Pregnancy Category:C
Breastfeeding: Amount of sufentanil ingested by the neonate are small and expected not to cause any adverse effects in breastfed infants on epidurally or IV use during labor/short time immediately postpartum. Sufentanil levels in milk is expected to increase if used for an extended period postpartum due to longer half-life while continous intravenous/repeated intravenous infusion. Due to lack of published data with repeated doses of IV use of sufentanil during lactation, other agents should be preferred, especially while nursing a newborn or preterm infant. If sufentanil is required by the nursing mother, limit maternal intake and supplement analgesia with a non narcotic analgesic. Advise patients to observe for signs of increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness and contact physician immediately is such signs occur. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 25 August 2011). As per manufacturer information it is not known whether sufentanil is excreted in human milk. Because fentanyl analogs are excreted in human milk, caution should be exercised while administering to nursing woman.

US Trade Name(s)
US Availability
sufentanil (generic)
- INJ: 50 mcg/mL (1, 2, 5 mL amp and vial)
Sufenta
- INJ: 50 mcg/mL (1, 2, 5 mL amp)

Canadian Trade Name(s)
Canadian Availability
sufentanil citrate (generic)
- INJ: 50 mcg/mL (1 mL amp)
- INJ: 50 mcg/mL (5 mL vials)

UK Trade Name(s)
UK Availability

Australian Trade Name(s)
Australian Availability
[Outline]



